Chronic Myeloproliferative Disorders  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chronic Myeloproliferative Disorders
PHCHBS-WD4070, NCT00718263: Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase)

Checkmark In 2nd line CML chronic phase pts
Feb 2014 - Feb 2014: In 2nd line CML chronic phase pts
Active, not recruiting
3
90
Japan, US, Europe, RoW
Nilotinib, Imatinib
Novartis Pharmaceuticals
Myelogenous Leukemia, Chronic
10/18
10/18
FAST, NCT02611973: Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia

Recruiting
3
2250
Europe
Aspirin therapy interruption, Usual treatment by aspirin 100 mg/d in the active comparator arm, No interruption of aspirin in the Observational arm, Hydroxyurea treatment (HU)
Assistance Publique - Hôpitaux de Paris
MPN, Essential Thrombocythemia
11/19
11/22

Download Options